Cervical cancer is the 4th most common cancer in women worldwide, with more than 300,000 women dying from it each year.
These deaths could have been easily prevented by timely screening and treatment.
60% of women screened in an initial visit for PAP or HPV, do not return for treatment.
We offer cervical cancer practitioners the convenience of having multiple needs met by a single supplier. Our comprehensive solution allows practitioners the flexibility to engage with Liger Medical for all their cervical cancer needs.
Liger Medical offers a full turnkey diagnostic and treatment program utilizing the EVAPro digital colposcope and theThermoGlide, for thermocoagulation treatment of precancerous lesions.
The single sitting “screen and treat” program allows us overcome the major challenge of loss to follow-up.
High proportions of loss to follow-up for cervical cancer patients have been reported in low and mid range income countries, ranging between 41–69%.2,3. The Liger Medical screening and treatment solutions reduces loss to follow up and increasing efficacy in diagnosis and treatment programs
Products
Products
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
Accessories
